Aprinoia Therapeutics key facts
- Aprinoia Therapeutics Inc is a clinical-stage biotechnology company.
- Aprinoia Therapeutics’s last known valuation is $295.5M.
- It has raised $65.0M; the latest was IPO ($5.5M) in Oct 2024.
- Notable investors include IMM Investment, Johnson & Johnson Innovation - JLABS, Woori Venture Partners, Suzhou Yuanfeng Capital Management, ShangPharma Innovation — 17 tracked in total.
- Status: Privately Held (backing).
Who backs Aprinoia Therapeutics
17+- ·The complete investor list: 17 names
- ·Watch Aprinoia Therapeutics: the Monday email on marks, rounds and moves
Aprinoia Therapeutics funding rounds
No funding rounds for Aprinoia Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Aprinoia Therapeutics valuation
Aprinoia Therapeutics's last known valuation is $295 million. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.
Aprinoia Therapeutics investors
17 investors are on record for Aprinoia Therapeutics, including IMM Investment, Johnson & Johnson Innovation - JLABS, Woori Venture Partners and Suzhou Yuanfeng Capital Management.
About Aprinoia Therapeutics
Aprinoia Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in protecting patients' brain health and changing clinical outcomes for a broad range of neurodegenerative diseases by developing novel, highly sensitive and selective diagnostic tools and novel therapeutics. Neurodegenerative diseases are relentless and largely fatal, resulting from progressive loss of nerve cells in the brain and, depending on the specific disorders, can affect a broad range of cognitive, behavioral, and motor functions, such as memory, thinking, speaking, walking, and breathing. It is developing several different diagnostic and therapeutic platforms such as abnormal protein aggregates of tau and alpha synuclein ("α-Syn") that are toxic to brain cells.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2015
- Employees
- 20
- Website
- aprinoia.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Aprinoia Therapeutics’s last known valuation. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.